



SEQUENCE LISTING

<110> Ribopharma AG
Kreutzer Dr., Roland
Limmer Dr., Stephan

<120> Method and Medicament for Inhibiting the Expression of a Given Gene

<130> 20200/2093D (400968)

<140> US 10/612,179

<141> 2003-07-02

<150> DE 199 03 713.2

<151> 1999-01-30

<150> DE 199 56 568.6

<151> 1999-11-24

<150> 09/889,802

<151> 2001-09-17

<150> PCT/DE00/00244

<151> 2000-01-29

<160> 8

<170> PatentIn version 3.2

<210> 1

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of the artificial sequence:
EcoRI cleavage site, T7 RNA Polymerase promoter

<400> 1

ggaattctaa tacgactcac tatagggcga tcagatctct agaag 45

<210> 2

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of the artificial sequence:
BamHI cleavage site, SP6 RNA Polymerase promoter

<400> 2

gggatccatt taggtgacac tatagaatac ccatgatcgc gtagtcgata 50

<210> 3

<211> 340
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of the artificial sequence:
 RNA which corresponds to a sequence from the positive control DNA
 of the HeLa Nuclear Extract in vitro transcription kit from
 Promega

<400> 3
 ucagaucucu agaagcuuua augcgguagu uaucaacagu uaaauugcua acgcagucag 60
 gcaccgugua ugaaaucuaa caaugcguc aucgucaucc ucggcaccgu caccucggau 120
 gcuguaggca uaggcuuggu uaugccggua cugccggggc ucuugcgga uaucguccau 180
 uccgacagca ucgccaguca cuauggcgug cugcuagcgc uauaugcguu gaugcaauuu 240
 cuaugcgcac ccguucucgg agcacugucc gaccgcuuug gccgccgcc aguccugcuc 300
 gcuucgcuac uuggagccac uaucgacuac gcgaucaugg 340

<210> 4
 <211> 363
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of the artificial sequence:
 DNA which corresponds to a sequence from the positive control DNA
 of the HeLa Nuclear Extract in vitro transcription kit from
 Promega

<400> 4
 tcagatctct agaagcttta atgcggtagt ttatcacagt taaattgcta acgcagtcag 60
 gcaccgtgta tgaaatctaa caatgcgctc atcgatcatcc tcggcaccgt caccctggat 120
 gctgtaggca taggcttggg tatgccggta ctgccggggc tcttgcgga tatcgatccat 180
 tccgacagca tcgccagtca ctatggcggtg ctgctagcgc tatatgcgtt gatgcaattt 240
 ctatgcgcac ccgttctcgg agcactgtcc gaccgctttg gccgccgcc agtcctgctc 300
 gcttcgctac ttggagccac tatcgactac gcgatcatgg cgaccacacc cgtcctgtgg 360
 atc 363

<210> 5
 <211> 315
 <212> RNA
 <213> Artificial Sequence

<220>

<223> Description of the artificial sequence:
Sequence from the YFP gene

<400> 5
auggugagca agggcgagga gcuguucacc gggguggugc ccauccuggu cgagcuggac 60
ggcgacguaa acggccacaa guucagcgug uccggcgagg gcgagggcga ugccaccuac 120
ggcaagcuga ccugaaguu caucugcacc accggcaagc ugcccugucc cuggcccacc 180
cucgugacca ccugaccua cggcgugcag ugcuucagcc gcuaccccga ccacaugaag 240
cagcacgacu ucuucaaguc cgccaugccc gaaggcuacg uccaggagcg caccaucuuc 300
uucaaggacg acggc 315

<210> 6
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of the artificial sequence:
EcoRI cleavage site, T7 RNA Polymerase promoter, complementary
region to the YFP gene

<400> 6
ggaattctaa tacgactcac tatagggcga atggtgagca agggcgagga gc 52

<210> 7
<211> 53
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of the artificial sequence:
BamHI cleavage site, SP6 RNA Polymerase promoter, complementary
region to the YFP gene

<400> 7
gggatccatt taggtgacac tatagaatac gccgtcgtcc ttgaagaaga tgg 53

<210> 8
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of the artificial sequence:
RNA which corresponds to a sequence from the YFP gene

<400> 8
ucgagcugga cggcgacgua a 21